Navigation Links
Mach One Executes Definitive Agreement to Acquire Biopharmaceutical Design & Engineering Firm
Date:2/11/2009

BELGIUM, WI, Feb. 11 /PRNewswire-FirstCall/ -- Mach One Corporation (Pink Sheets: MNCN), a global health company that develops biotechnology based solutions that produce positive, long term benefit to the agricultural and consumer markets, announced today that it has executed its definitive agreement to acquire Modular Process Constructors LLC.

The purchase price of $500,000 in the form of Convertible Preferred Stock with a conversion price of .50 per share will allow Mach One to bring in house the engineering and design experience needed to roll out its capacity expansion on a national basis -- plans that include up to 17 facilities nationally. Bringing needed in-house expertise along with the ability to engineer and design systems for world class customers, Mach One takes an important step in building their internal expertise for organic growth.

Monte B. Tobin, Chairman and Chief Executive Officer of Mach One, said, "We welcome the expertise to facilitate expansion of our business model internally combined with key engineering experts who are able to work externally with world class customers in the biopharmaceutical industry."

"This is yet another major building block Mach One is leveraging to advance our business plan through our new director, Tad M. Ballantyne. Tad joined the board with our recent acquisition of Pacific Rim Foods Ltd. and is also Managing Director of the parent company of Modular Process Constructors LLC. Through these key associations, Mr. Ballantyne has provided both capital and technology to Mach One in the execution of our business model. It's important to see that our acquisition strategy is accretive to our core business by the addition of not only revenues and assets, but of highly specialized knowledge and expertise," added Tobin.

About Mach One Corporation:

Mach One Corporation (www.machonecorp.com) is a global health company that provides biotechnology based solutions to help address one of the world's most pressing and costly needs -- positive, long-term health and longevity benefits for disease-threatened animals of large commercial operations. Mach One provides broad spectrum immunoglobulin and nutraceutical products that offer a new level of cost effectiveness, improved health and ease of treatment -- with an initial focus on the dairy industry. Mach One intends to fully leverage the potential of its breakthrough solutions -- breakthroughs that one day will also include consumer applications.

Cautionary Statement: This news release may include certain "Forward-looking statements" within the meaning of Section 21E of the United States Securities Exchange Act, as amended. All statements, other than statements of historical fact, included in this release are forward-looking statements that involve various risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. This notice expressly qualifies all forward-looking statements in this release.


'/>"/>
SOURCE Mach One Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Powersafe Technology Corp. Recapitalizes, Executes Merger Agreement with Amplification Technologies, and Invests in Amplification
2. Diamyd Strengthens Financial Position and Executes a Fully Subscribed Direct Placement
3. Rosetta Genomics Executes Binding Term Sheet to Acquire U.S. CLIA-Certified Lab to Expedite Commercialization of Diagnostic Tests
4. New Edition of Definitive Resource in Tissue Engineering Released Today
5. Arrow International Files and Mails Definitive Proxy Materials
6. IsoTis Files Definitive Proxy Statement
7. Acorn Acquisition Corp Announces Definitive Agreement to Acquire Lumen Medical Inc.
8. Elbit Medical Imaging Ltd. Announces Definitive Agreements for a Large Scale Luxury Mixed Use Project in Bangalore, India
9. Nabi Biopharmaceuticals Announces Mailing of Definitive Proxy Statement and Release Date of Third Quarter 2007 Financial Results
10. Advanced Life Sciences Enters Into Definitive Securities Purchase Agreements for $20 Million with New and Existing Institutional Investors
11. Bayer HealthCare Affiliate MEDRAD and Possis Medical Sign Definitive Merger Agreement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... MELBOURNE, Australia , Dec. 6, 2016  The ... Health Informatics Society of Australia (HISA) today announced ... technology startup exchange program between Australia ... city in the world. HISA and ... are initiating a program to create a global health ...
(Date:12/5/2016)... 2016 Axovant Sciences Ltd. (NYSE: ... the treatment of dementia, today announced that data on ... Alzheimer,s disease will be presented at the 2016 Clinical ... 9, 2016 in San Diego . ... simple and complex measures of activities of daily living ...
(Date:12/5/2016)... ... December 05, 2016 , ... The Real Dirt ... premier cannabis technology and application experts, Chip Baker. Chip Baker formerly co-founded Royal ... the past 30 years, Chip Baker other industry veterans have made the evolution ...
(Date:12/5/2016)... , Dec. 5, 2016  Renova™ Therapeutics, ... congestive heart failure and other chronic diseases, announced ... the company as Chief Financial Officer (CFO), effective ... with 20 years of experience in financial management ... biotech and software companies. Most recently, Ms. Bovenizer ...
Breaking Biology Technology:
(Date:11/19/2016)... 18, 2016 Securus Technologies, a leading provider ... safety, investigation, corrections and monitoring, announced today that it ... to have an independent technology judge determine who has ... high tech/sophisticated telephone calling platform, and the best customer ... do most of what we do – which clearly ...
(Date:11/17/2016)... it has just released a new white paper authored by Zettar that covers the ... transfer storage solutions. Photo - http://photos.prnewswire.com/prnh/20161116/440463 ... ... ... Setting up a high performance computing or HPC system can be a complicated endeavor ...
(Date:11/15/2016)... , Nov. 15, 2016  Synthetic Biologics, Inc. ... therapeutics focused on the gut microbiome, today announced ... 25,000,000 shares of its common stock and warrants ... at a price to the public of $1.00 ... Synthetic Biologics from the offering, excluding the proceeds, ...
Breaking Biology News(10 mins):